Navigation Links
SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
Date:4/22/2009

ST. LOUIS, April 23 /PRNewswire-FirstCall/ -- SAFC Biosciences(R), a business segment within SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: SIAL), today announced the introduction of EX-CELL(TM) EBx(R) cell growth and viral production media designed exclusively to support Vivalis' (NYSE Euronext: VLS) EB66(R) duck cells used in the commercial production of prophylactic and therapeutic vaccines. The new EX-CELL EBx media is expected to further enable EB66 licensees in the development of viral vaccine therapeutics. In addition, Vivalis plans to use the media in the cGMP manufacture of vaccine lots to support phase I/II clinical trials.

Vivalis, a leader in embryonic stem cell technology, has developed its fully-documented EB66 cell line from duck embryonic stem cells. The cell line fulfils all current industrial specifications for biologics manufacturing while retaining most of the desirable features of embryonic stem cells, such as genetic stability and indefinite cell proliferation. The EB66 cell line also provides key qualities for industrial applications, including growth in serum-free medium, proliferation in bioreactors at high cell densities such as suspension cells, and demonstrates high susceptibility to a broad range of genetically engineered and wild type animal and human viruses.

Commenting on the introduction of EX-CELL(TM) EBx(R), Bruce Lehr, SAFC Bioscience's Marketing Director, said: "Following our strategy of providing customer-centric solutions, we have worked closely with Vivalis to develop these new media to cGMP standards. Looking ahead, we expect to continue expanding our serum-free virus/vaccine media offer to keep pace with the market's burgeoning demand for safer, faster, more economical production processes."

Pierre Miniou, Vivalis Director, Business
'/>"/>

SOURCE Sigma-Aldrich Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
2. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
3. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
4. DuPont and USDA ARS to Collaborate on New E. coli Test in Beef
5. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
6. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
7. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
8. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
9. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
10. febit and TGen Collaborate to Study New DNA Capture Method
11. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...e-FirstCall/ -- Biotel Inc. (OTC Bulletin Board: B... September 30, 2009 with net earnings of $128,000,...,000. This compares to net earnings of $328,000, ...000 for the first quarter of last year. ,, Comm...ent and CEO Steve Springrose said: "Biotel enjoyed...
(Date:11/20/2009)... BD (Becton, Dickinson an...letion of its acquisition of HandyLab, Inc., an An...manufactures molecular diagnostic assays and autom...b announced an exclusive agreement for BD to devel...Lab Jaguar(TM) platform, the first fully integrate...
(Date:11/19/2009)...wswire/ -- Warner Chilcott plc (Nasdaq: WCRX ) to...ced secondary offering of 20,000,000 of its ordina...hare. The selling shareholders include funds affi...nking, J.P. Morgan Partners (advised by CCMP Capit...r institutional investors and members of the Compa...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Ikaria 28R 29 Names New Chairman 14523 1Ikaria 28R 29 Names New Chairman 14523 2Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 1Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 4Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 6Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 7
... groups set out to confirm potential benefits of a...th breast cancer, PARIS, May 27 A new internatio...er is open for enrollment. The pivotal BETH,(BEvac...sitive Breast,Cancer) study is a Phase III clinica...s of combining two monoclonal antibodies, the anti...
...on A/S Today Announces That it has Entered Into a ...ity of Texas M. D., Anderson Cancer Center to De... Cancer, VEDBAEK, Denmark...alue gene expression analysis products, today,anno...agreement with the,Kleberg Center for Molecular Ma...
Other Medicine Technology:First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer 2First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer 3First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer 4Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center 2Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center 3
(Date:11/21/2009)...ASHINGTON, Nov. 21 DNC ...after the Senate voted to begin full debate of hea...ttp://www.newscom.com/cgi-bin/prnh/20080519/DNCLOG...ic step on the road to enacting health insurance r...enators will now have an opportunity to debate the...
(Date:11/21/2009)... LONDON, November 21, 2009 /PRNewswire-FirstCall/ ...st Test Test Test Test Test Test Test Test Test,Te...st Test Test Test Test,Test Test Test Test Test Te...est More test More test More test More test More t...est More test More test More test More,test More t...
(Date:11/21/2009)... New Haven Dental Group merges their p...ranford, CT. , (PRWEB) No...prised of partners Dr. David Gibson, Dr. Dean Clou...has just merged their growing practice with that o...en Dr. Pickman decided he wanted to retire from de...
(Date:11/20/2009)..., WASHINGTON, Nov. 20 ...rged the Senate to make essential changes its heal...aw on abortion funding and conscience protection o...grants and include strong provisions for adequate ... health care bill an "enormous disappointment" tha...
(Date:11/20/2009)... ST. LOUIS, Nov. 20 Ce...hat it will present at the Bank of America Merrill... 2-3, 2009, at the Crowne Plaza Hotel Times Square...esday, December 2nd at 8:30 a.m. Eastern Time. Inv...ive, audio webcast of Centene,s presentation at: ...
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:New Haven Dental Group Expands Their Vision 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2
...he dangers of sun exposure that are backed by rese...a person's risk of developing skin// cancer, Ameri...ublished in the Journal of the American Academy of...ercent increase since 1999. However, this percenta...
...alth (MOH) says that Singapore will soon conduct a...mic Readiness.// More than 1,000 personnel ... the Ministry of Education, the Civil Aviation Aut... The two-day emergency exercise endeavors to si...
...earchers, in collaboration with investigators at J...rial to test// a new vaccine against the West Nile...cause serious illness, is making its yearly appear...ille have tested positive for the virus. "Wh...
... memory begins to decline, executive function is t...ession from mild cognitive// impairment, a pre-Alz.... Ron Petersen, M.D., Ph.D., Mayo Clinic neu...omeone with mild cognitive impairment starts havin...
... admissions given to 23 students in a post-graduat...rrent academic year. // "The division bench ...eld that the college administration had not conduc... behalf of two students who had filed a case again...
... Roche are conducting talks to make the expensive ...able.// According to Health Minister Tony Abbo...the delay in rushing Herceptin on to the Pharmaceu...ossible deal for patients. So we are to some exten...
Other Medicine News:Health News:Age and Socioeconomic Factors Are Strongest Determinants of Sunburn 2Health News:Age and Socioeconomic Factors Are Strongest Determinants of Sunburn 3Health News:University Participating in West Nile Vaccine Trial 2Health News:Decline in Concentration, Decision-Making and Problem-Solving 2
...CellaVision DM96 is an Automated Digital Cell Morp...e-classification/characterization, display, storag...es. Up to 96 stained peripheral blood smears can b... 60 per hour depending on the tests requested. Usi...
Cystoscopy "T". Drape, Sterile
Urological Drape
... the Penilab IV and the Penilab V have an exceptio...tal studies. Model 1060 is similar to the Model 1... can one be added later. The Penilab V has a Dopp... of the accessories you'll need to get started. L...
Medicine Products: